Author

K. Clise-Dwyer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Organism:human· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell-cell communication· 1

Frequent Co-Authors

F. Ma· 2 shared S. Colla· 2 shared B. D. Vaillant· 1 shared B. Patel· 1 shared D. Hammond· 1 shared D. Kumar· 1 shared E. M. Park· 1 shared F. G. Giancotti· 1 shared

Activity by Year

2023-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

F. Ma

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

IL-1B-mediated inflammatory signaling drives ineffective erythropoiesis in early-stage myelodysplastic syndromes

V. Adema, I. Ganan-Gomez, F. Ma, J. J. Rodriguez-Sevilla, K. Chien, H. Yang, N. Thongon, R. Kanagal-Shamanna, S. Loghavi, G. Montalban-Bravo, D. Hammond, Y. Gu, R. Tan, L. Tan, P. Lorenzi, , S. Colla

This study shows that IL-1B-mediated inflammation drives ineffective erythropoiesis in early-stage MDS and that canakinumab can reduce transfusion dependence in patients with DNMT3A and TET2 mutations.

bioRxiv · Sep 28, 2023 · PreprintCancer Biology

Triggering receptor expressed on myeloid cells 2 (TREM2) regulates phagocytosis in glioblastoma

M. M. Peshoff, P. Gupta, R. Trivedi, S. Oberai, P. Chakrapani, M. Dang, N. K. Milam, M. E. Maynard, B. D. Vaillant, J. T. Huse, L. Wang, K. Clise-Dwyer, K. P. Bhat

This study shows TREM2 promotes phagocytosis in gliomas and is not linked to immunosuppression, suggesting TREM2 activation could enhance immunotherapy for brain tumors.

bioRxiv · Apr 5, 2023Cancer Biology

STAT3 protects HSCs from intrinsic interferon signaling and loss of long-term blood-forming activity

B. Patel, Y. Zhou, R. L. Babcock, F. Ma, M. A. Zal, D. Kumar, Y. B. Medik, L. M. Kahn, J. E. Pineda, E. M. Park, X. Tang, M. G. Raso, T. Zal, K. Clise-Dwyer, F. G. Giancotti, , S. S. Watowich

This study shows that STAT3 is essential for maintaining hematopoietic stem cell function by suppressing interferon signaling and myeloid skewing, and its loss leads to impaired hematopoietic activity.

bioRxiv · Feb 10, 2023 · PreprintImmunology